RNS Number: 9043 F Nuformix PLC 18 July 2019 For a printer friendly copy of this announcement, please click on the link below to open a pdf version. o Achieved first pre-clinical milestone resulting in receipt of a first payment of £500,000 in accordance with its Newsummit Biopharma licensing agreement. o After the year end Nuformix announced achievement of a...
RNS Number: 4977 B Nuformix PLC 07 June 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 3506 B Nuformix PLC 06 June 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 6210 A Nuformix PLC 30 May 2019. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 6205 A Nuformix PLC 30 May 2019. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Cambridge, UK, 30 May 2019: Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, is pleased to announce positive results in its clinical study for the Company's lead programme NXP001.. ·Confirm NXP001's potential for development as a treatment for CINV, enabling...
RNS Number: 2045 A Nuformix PLC 24 May 2019 The following amendment has been made to the' Notification Major Share Interests' announcement released on 24 May 2019 at 07.30 under RNS No. 1041 A.. Corrections have been made to TR1 entries 5 and 6.. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 1041 A Nuformix PLC 24 May 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 1024 A Nuformix PLC 24 May 2019. Cambridge, UK, 16 May 2019: Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces that it has received notice from Mr Alan Miller in accordance with the Convertible Loan Agreement dated 18 April 2017 to convert the...
RNS Number: 7642 Z Nuformix PLC 22 May 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 7647 Z Nuformix PLC 22 May 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 7649 Z Nuformix PLC 22 May 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 1666 Z Nuformix PLC 15 May 2019. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Nuformix plc
NFX.L
Nuformix plc
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    460.75M

Featured Media

Company Profile

Nuformix is a pharmaceutical development company using cocrystal technology, unlocking the therapeutic potential of approved drugs with lead programmes in oncology supportive care and fibrosis.

Classification

Market Indices-

Locations

HQ
153 Cambridge Science Park
Milton Road
Cambridge
CB4 0GH
Watchlist